Rigel Pharmaceuticals, Inc.
Compositions and methods for inhibition of the JAK pathway

Last updated:

Abstract:

The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

Status:
Grant
Type:

Utility

Filling date:

26 Aug 2019

Issue date:

14 Dec 2021